From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Fingolimod or Gilenya (brand name) is a drug licensed for use in adults and children aged over 20 with relapsing-remitting multiple sclerosis.[1] Fingolimod may module TRPM7.

Theory[edit | edit source]

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

No clinician trials have been conducted for ME/CFS patients using fingolimod.

Costs and availability[edit | edit source]

Perscription only drug.

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]